• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Tonix Pharmaceuticals Holding Corp (TNXP)

Common Shares
Sell: $19.30|Buy: $19.62|Change: 0.91 (4.90%)

Not yet a customer?

Low cost dealing from £1.50

Choose from our range of SIPP, ISA and Dealing accounts

Find out more

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targetingCD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Address

509 Madison Avenue
Suite 306
New York
NY
USA
10022

Telephone

+1 212 980-9155

Website

https://www.tonixpharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Tonix Pharmaceuticals Holding Corp Second Quarter Earnings Results for 20262026-08-11T00:00:00
Tonix Pharmaceuticals Holding Corp First Quarter Earnings Results for 20262026-05-12T00:00:00
Tonix Pharmaceuticals Holding Corp Annual General Meeting for 20262026-05-08T11:00:00
Tonix Pharmaceuticals Holding Corp Fourth Quarter Earnings Results for 20252026-03-18T16:30:00
Tonix Pharmaceuticals Holding Corp Annual Report for 20252026-03-18T00:00:00
Tonix Pharmaceuticals Holding Corp Third Quarter Earnings Results for 20252025-11-12T00:00:00

Previous key dates

NameKey Date
Cantor Global Healthcare Conference 20252025-09-04T13:35:00
Tonix Pharmaceuticals Discussion of Tonmya™ Approval2025-08-18T08:30:00
Tonix Pharmaceuticals Holding Corp Second Quarter Earnings Results for 20252025-08-11T00:00:00
Tonix Pharmaceuticals Holding Corp First Quarter Earnings Results for 20252025-05-12T00:00:00
Tonix Pharmaceuticals Holding Corp Annual General Meeting for 20252025-05-08T11:00:00
2025 Jones Trading Healthcare and Innovation Conference2025-04-09T10:00:00
Tonix Pharmaceuticals Holding Corp Fourth Quarter Earnings Results for 20242025-03-18T16:30:00
Tonix Pharmaceuticals Holding Corp Annual Report for 20242025-03-18T00:00:00
Zacks SCR Life Sciences Virtual Investor Forum2025-03-13T15:30:00
2025 Virtual Investor Summit2025-03-11T10:30:00
NobleCon20 Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference2024-12-03T12:00:00
Tonix Pharmaceuticals Holding Corp Winter Investor Summit Virtual 20242024-11-21T10:00:00
Tonix Pharmaceuticals Holding Corp Third Quarter Earnings Results for 20242024-11-12T00:00:00
World Vaccine Congress Europe2024-10-30T14:10:00
Special Meeting of Shareholders2024-10-30T11:00:00
ThinkEquity Conference 20242024-10-30T09:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.